Physician profile
Robert L Laughlin
NPI 1548209711
$10,334.54
in general payments reported to CMS, 2019-2025
36 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,500 · 2020: $989 · 2021: $1,169 · 2022: $3,061 · 2023: $1,185 · 2024: $1,339 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,581 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,581.28 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $2,220.19 | 2022 | |
| Glaxosmithkline, LLC. | $1,859.29 | 2019-2025 | Nucala, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $1,309.29 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,194.61 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $955.38 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Insmed, INC. | $321.19 | 2019-2023 | Arikayce |
| Grifols USA, LLC | $249.97 | 2020-2024 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $229.18 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $205.95 | 2019-2025 | Winrevair |
| United Therapeutics Corporation | $180.83 | 2019-2024 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $162.16 | 2020-2023 | Glassia |
| Pfizer INC. | $149.35 | 2020-2024 | |
| Inspire Medical Systems, INC. | $140.25 | 2019 | |
| Sunovion Pharmaceuticals INC. | $139.59 | 2019-2020 | |
| Genentech USA, INC. | $139.55 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $124.77 | 2021-2024 | |
| Amgen INC. | $102.75 | 2025 | Tezspire |
| Pulmonx Corporation | $91.03 | 2024-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Baxter Healthcare | $70.74 | 2023-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Advanced Respiratory, INC | $64.73 | 2019 | |
| Astellas Pharma US INC | $57.16 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $53.64 | 2019-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $37.49 | 2020-2021 | |
| Tactile Systems Technology INC | $36.40 | 2024 | Flexitouch Plus, Entre Plus |
| Verona Pharma, INC. | $32.50 | 2025 | Ohtuvayre |
| Optinose US, INC. | $26.28 | 2024 | |
| Philips North America LLC | $23.57 | 2025 | Vest Therapy Und |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.53 | 2023 | Lifevest |
| Stimlabs LLC | $20.64 | 2025 | Corplex P |
| Mylan Specialty L.P. | $20.13 | 2023 | Yupelri |
| Pinnacle Biologics, INC | $19.14 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.01 | 2019 | |
| Gilead Sciences, INC. | $15.59 | 2025 | |
| Mallinckrodt Hospital Products INC. | $15.13 | 2022 | |
| Smith+Nephew, INC. | $14.82 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Laughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.